CD274 and gastric cancer: Recently, the combination of the programmed death-1 (PD-1) inhibitor, nivolumab, with cytotoxic chemotherapy has shown survival benefits in unresectable advanced or metastatic GC and has become the standard first-line treatment for patients with a PD-L1 combined positive score (CPS) of 5 or higher6.